CHEMBIO DIAGNOSTICS, INC.
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $49.5M | $47.8M | $32.5M | $34.5M | $34.6M | $24.0M |
| Operating income | −$23.6M | −$31.1M | −$23.1M | −$13.3M | −$8.0M | −$6.5M |
| Net income | −$23.3M | −$33.9M | −$25.5M | −$13.7M | −$7.9M | −$6.4M |
| Total assets | $62.6M | $73.3M | $64.9M | $55.7M | $40.9M | $16.6M |
| Total liabilities | $44.8M | $39.0M | $37.1M | $31.7M | $7.6M | $3.5M |
| Equity | $17.8M | $34.3M | $27.8M | $24.0M | $33.3M | $13.1M |
| EPS (diluted) | $-0.72 | $-1.40 | $-1.34 | $-0.81 | $-0.54 | $-0.52 |
| Shares out. | 30.1M | 20.2M | 17.7M | 17.2M | 14.2M | 12.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −47.7%
- Net margin
- −47.0%
- Return on equity
- −130.9%
- Return on assets
- −37.2%
- Return on capital (ROCE)
- −101.4%
- Liabilities / assets
- 71.6%
- Debt / equity
- 2.52×
- Book value / share
- $0.59
- Revenue growth (YoY)
- 3.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -9.20distress
- Accruals / assets
- −16.9%clean
- Beneish M-Score
- -3.73normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Regulation FD disclosureApr 27, 2023
- Delisting / listing-standard noticeApr 6, 2023
- Other material eventMar 21, 2023
- Other material eventMar 15, 2023
- Other material eventFeb 24, 2023
- Entered a material agreement · Other material eventJan 31, 2023
- Results of operations · Regulation FD disclosureNov 4, 2022
- Delisting / listing-standard noticeOct 4, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.